Your browser doesn't support javascript.
loading
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles, D; Ciruelos, E; Schneeweiss, A; Puglisi, F; Peretz-Yablonski, T; Campone, M; Bondarenko, I; Nowecki, Z; Errihani, H; Paluch-Shimon, S; Wardley, A; Merot, J-L; Trask, P; du Toit, Y; Pena-Murillo, C; Revelant, V; Klingbiel, D; Bachelot, T.
Afiliación
  • Miles D; Mount Vernon Cancer Centre, Northwood, UK. Electronic address: David.miles@doctors.org.uk.
  • Ciruelos E; Medical Oncology Department Breast Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; HM Hospitales, Madrid, Spain.
  • Schneeweiss A; Gynecologic Oncology Division, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany.
  • Puglisi F; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Centro di Riferimento Oncologico Aviano-National Cancer Institute, Aviano, Italy; Department of Medicine, University of Udine, Udine, Italy.
  • Peretz-Yablonski T; Sharett Institute of Oncology and Center for Malignant Breast Diseases, Hadassah Medical Organization, Jerusalem, Israel.
  • Campone M; Institut de Cancérologie de l'Ouest, Angers, France.
  • Bondarenko I; Oncology and Medical Radiology Department, City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine.
  • Nowecki Z; Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland.
  • Errihani H; National Institute of Oncology, Mohammed V Rabat University, Rabat, Morocco.
  • Paluch-Shimon S; Division of Oncology, Sheba Medical Centre, Tel Hashomer, Israel.
  • Wardley A; National Institute for Health Research Manchester Clinical Research Facility at the Christie NHS Foundation Trust, Manchester, UK; Outreach Research & Innovation Group, Manchester, UK.
  • Merot JL; IQVIA, La Défense, France.
  • Trask P; Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, USA.
  • du Toit Y; Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Pena-Murillo C; Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Revelant V; Global Product Development, Portfolio Clinical Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Klingbiel D; Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Bachelot T; Medical Oncology Department, Centre Léon Bérard, Lyon, France.
Ann Oncol ; 32(10): 1245-1255, 2021 10.
Article en En | MEDLINE | ID: mdl-34224826
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article